7b, a novel naphthalimide derivative, exhibited anti-inflammatory effects via targeted-inhibiting TAK1 following down-regulation of ERK1/2- and p38 MAPK-mediated activation of NF-κB in LPS-stimulated RAW264.7 macrophages.

[1]  M. Schröder,et al.  A Novel IRAK1–IKKε Signaling Axis Limits the Activation of TAK1–IKKβ Downstream of TLR3 , 2013, The Journal of Immunology.

[2]  Yufang Xu,et al.  7b, a novel amonafide analog, inhibited proliferation and phorbol 12-myristate 13-acetate/phytohemagglutinin-induced inflammatory responses of Jurkat T cells via p73-dependent pathway and decrease of nuclear factor-κB DNA-binding, respectively , 2013, Leukemia & lymphoma.

[3]  Jung-Hye Choi,et al.  Roxatidine suppresses inflammatory responses via inhibition of NF‐κB and p38 MAPK activation in LPS‐induced RAW 264.7 macrophages , 2011, Journal of cellular biochemistry.

[4]  Yufang Xu,et al.  7-b, a novel amonafide analogue, cause growth inhibition and apoptosis in Raji cells via a ROS-mediated mitochondrial pathway. , 2011, Leukemia research.

[5]  Mun Kyung Hwang,et al.  Cyanidin suppresses ultraviolet B-induced COX-2 expression in epidermal cells by targeting MKK4, MEK1, and Raf-1. , 2010, Biochemical pharmacology.

[6]  C. Dinarello.  Anti-inflammatory Agents: Present and Future , 2010, Cell.

[7]  M. Karin,et al.  Immunity, Inflammation, and Cancer , 2010, Cell.

[8]  Yufang Xu,et al.  A new class of naphthalimide-based antitumor agents that inhibit topoisomerase II and induce lysosomal membrane permeabilization and apoptosis. , 2010, Journal of medicinal chemistry.

[9]  T. Lawrence.  The nuclear factor NF-kappaB pathway in inflammation. , 2009, Cold Spring Harbor perspectives in biology.

[10]  M. Lv,et al.  Overview of naphthalimide analogs as anticancer agents. , 2009, Current medicinal chemistry.

[11]  C. Rivas,et al.  Activation of NF-kB Pathway by Virus Infection Requires Rb Expression , 2009, PloS one.

[12]  R. Pereira.  Selective cyclooxygenase-2 (COX-2) inhibitors used for preventing or regressing cancer. , 2009 .

[13]  R. Kiss,et al.  Naphthalimides and azonafides as promising anti-cancer agents. , 2009, Current medicinal chemistry.

[14]  E. Bradley,et al.  TGF-beta coordinately activates TAK1/MEK/AKT/NFkB and SMAD pathways to promote osteoclast survival. , 2008, Experimental cell research.

[15]  E. Mendis,et al.  Inhibition of inducible nitric oxide synthase and cyclooxygenase‐2 in lipopolysaccharide‐stimulated RAW264.7 cells by carboxybutyrylated glucosamine takes place via down‐regulation of mitogen‐activated protein kinase‐mediated nuclear factor‐κB signaling , 2008, Immunology.

[16]  S. Ghosh,et al.  Shared Principles in NF-κB Signaling , 2008, Cell.

[17]  M. Itakura,et al.  PKC412 (CGP41251) modulates the proliferation and lipopolysaccharide-induced inflammatory responses of RAW 264.7 macrophages. , 2007, Biochemical and biophysical research communications.

[18]  Yiwei Li,et al.  Back to the future: COX-2 inhibitors for chemoprevention and cancer therapy. , 2007, Mini reviews in medicinal chemistry.

[19]  Wan-Wan Lin,et al.  A cytokine-mediated link between innate immunity, inflammation, and cancer. , 2007, The Journal of clinical investigation.

[20]  B. Masters,et al.  Oxygen Metabolism by Neuronal Nitric-oxide Synthase* , 2007, Journal of Biological Chemistry.

[21]  N. Lajis,et al.  Cardamonin inhibits COX and iNOS expression via inhibition of p65NF-κB nuclear translocation and Iκ-B phosphorylation in RAW 264.7 macrophage cells , 2007 .

[22]  S. Dong,et al.  Nuclear Factor-κB p65 Inhibits Mitogen-Activated Protein Kinase Signaling Pathway in Radioresistant Breast Cancer Cells , 2006, Molecular Cancer Research.

[23]  C. Kamei,et al.  Involvement of cyclooxygenase-2 in allergic nasal inflammation in rats. , 2006, International immunopharmacology.

[24]  R. Jain,et al.  The role of nitric oxide in tumour progression , 2006, Nature Reviews Cancer.

[25]  J. Jun,et al.  Differential activation of mitogen activated protein kinases and nuclear factor-κB in lipopolysaccharide-treated term and preterm amnion cells , 2005, Virchows Archiv.

[26]  H. Schreiber,et al.  Inflammation as a tumor promoter in cancer induction. , 2004, Seminars in cancer biology.

[27]  B. Robinson,et al.  Fluorescent Sugar and Uridine Conjugates of 1,8-Naphthalimides with Methyl and Ferrocenyl Headgroups , 2004 .

[28]  Sang -Geon Kim,et al.  Inhibition of lipopolysaccharide‐inducible nitric oxide synthase, TNF‐α and COX‐2 expression by sauchinone effects on I‐κBα phosphorylation, C/EBP and AP‐1 activation , 2003, British journal of pharmacology.

[29]  M. Harada,et al.  Molecular mechanisms of lipopolysaccharide-induced cyclooxygenase-2 expression in human neutrophils: involvement of the mitogen-activated protein kinase pathway and regulation by anti-inflammatory cytokines. , 2002, International immunology.

[30]  T. Lawrence,et al.  Possible new role for NF-κB in the resolution of inflammation , 2001, Nature Medicine.

[31]  H. Bartsch,et al.  Nuclear Factor κB Is a Molecular Target for Sulforaphane-mediated Anti-inflammatory Mechanisms* , 2001, The Journal of Biological Chemistry.

[32]  C. Cooper,et al.  Nitric oxide synthases: structure, function and inhibition , 2001 .

[33]  N. Mackman,et al.  LPS induction of gene expression in human monocytes. , 2001, Cellular signalling.

[34]  R. Gaynor,et al.  Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer. , 2001, The Journal of clinical investigation.

[35]  Jongdae Lee,et al.  TAK1 regulates multiple protein kinase cascades activated by bacterial lipopolysaccharide , 2000, Journal of leukocyte biology.

[36]  Qingbo Xu,et al.  Activation, differential localization, and regulation of the stress-activated protein kinases, extracellular signal-regulated kinase, c-JUN N-terminal kinase, and p38 mitogen-activated protein kinase, in synovial tissue and cells in rheumatoid arthritis. , 2000, Arthritis and rheumatism.

[37]  J. Ninomiya-Tsuji,et al.  TAK1 Mitogen-activated Protein Kinase Kinase Kinase Is Activated by Autophosphorylation within Its Activation Loop* , 2000, The Journal of Biological Chemistry.

[38]  T. Muta,et al.  TAK1 mediates an activation signal from toll‐like receptor(s) to nuclear factor‐κB in lipopolysaccharide‐stimulated macrophages , 2000, FEBS letters.

[39]  H. Maeda,et al.  Nitric oxide and oxygen radicals in infection, inflammation, and cancer. , 1998, Biochemistry. Biokhimiia.

[40]  E. Zandi,et al.  The IκB Kinase Complex (IKK) Contains Two Kinase Subunits, IKKα and IKKβ, Necessary for IκB Phosphorylation and NF-κB Activation , 1997, Cell.

[41]  Carl Nathan,et al.  Nitric oxide synthases: Roles, tolls, and controls , 1994, Cell.

[42]  C. Nathan,et al.  Role of transcription factor NF-kappa B/Rel in induction of nitric oxide synthase. , 1994, The Journal of biological chemistry.

[43]  A. Ristimäki,et al.  Cyclooxygenase Gene Expression in Inflammation and Angiogenesis a , 1993, Annals of the New York Academy of Sciences.

[44]  M. Marletta,et al.  Nitric oxide synthase structure and mechanism. , 1993, The Journal of biological chemistry.

[45]  D. Baltimore,et al.  I kappa B: a specific inhibitor of the NF-kappa B transcription factor. , 1988, Science.

[46]  J. Hong,et al.  Inhibition of TAK1 by kamebakaurin in dendritic cells. , 2013, International immunopharmacology.

[47]  F. Bosetti,et al.  Targeting cyclooxygenases-1 and -2 in neuroinflammation: Therapeutic implications. , 2011, Biochimie.

[48]  Xin Lin,et al.  NF-κB signaling pathways regulated by CARMA family of scaffold proteins , 2011, Cell Research.

[49]  S. Mariathasan,et al.  Inflammasome adaptors and sensors: intracellular regulators of infection and inflammation , 2007, Nature Reviews Immunology.

[50]  C. Tsatsanis,et al.  Signalling networks regulating cyclooxygenase-2. , 2006, The international journal of biochemistry & cell biology.

[51]  M. Karin,et al.  Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. , 2000, Annual review of immunology.

[52]  C. Nathan,et al.  Nitric oxide and macrophage function. , 1997, Annual review of immunology.